

Proceedings

Open Access

Rheumatoid arthritis-associated gene-gene interaction network for rheumatoid arthritis candidate genes

Chien-Hsun Huang¹, Lei Cong¹, Jun Xie², Bo Qiao¹, Shaw-Hwa Lo^{*1} and Tian Zheng^{*1}

Addresses: ¹Department of Statistics, Columbia University, 1255 Amsterdam Avenue, 10th Floor, MC44690, New York, New York 10027, USA and ²Department of Statistics, 250 North University Street, Purdue University, West Lafayette, Indiana 47907, USA

E-mail: Chien-Hsun Huang - ch2526@columbia.edu; Lei Cong - congl@stat.columbia.edu; Jun Xie - junxie@stat.purdue.edu; Bo Qiao - bq2108@columbia.edu; Shaw-Hwa Lo* - slo@stat.columbia.edu; Tian Zheng* - tzheng@stat.columbia.edu

*Corresponding author

from Genetic Analysis Workshop 16
St Louis, MO, USA 17-20 September 2009

Published: 15 December 2009

BMC Proceedings 2009, 3(Suppl 7):S75 doi: 10.1186/1753-6561-3-S7-S75

This article is available from: <http://www.biomedcentral.com/1753-6561/3/S7/S75>

© 2009 Huang et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Rheumatoid arthritis (RA, MIM 180300) is a chronic and complex autoimmune disease. Using the North American Rheumatoid Arthritis Consortium (NARAC) data set provided in Genetic Analysis Workshop 16 (GAW16), we used the genotype-trait distortion (GTD) scores and proposed analysis procedures to capture the gene-gene interaction effects of multiple susceptibility gene regions on RA. In this paper, we focused on 27 RA candidate gene regions (531 SNPs) based on a literature search. Statistical significance was evaluated using 1000 permutations. *HLA-DRB1* was found to have strong marginal association with RA. We identified 14 significant interactions ($p < 0.01$), which were aggregated into an association network among 12 selected candidate genes *PADI4*, *FCGR3*, *TNFRSF1B*, *ITGAV*, *BTLA*, *SLC22A4*, *IL3*, *VEGF*, *TNF*, *NFKB1*, *TRAF1-C5*, and *MIF*. Based on our and other contributors' findings during the GAW16 conference, we further studied 24 candidate regions with 336 SNPs. We found 23 significant interactions (p -value < 0.01), nine interactions in addition to our initial findings, and the association network was extended to include candidate genes *HLA-A*, *HLA-B*, *HLA-C*, *CTLA4*, and *IL6*. As we will discuss in this paper, the reported possible interactions between genes may suggest potential biological activities of RA.

Background

Rheumatoid arthritis (RA) is a common inflammatory disorder with complex etiology. Although the causes of RA are still unclear, it is believed to be attributed to both genetic and environmental factors. During the last few decades, many new genetic regions have been identified

to associate with RA. Remmers et al. [1] showed that *STAT4* was an important genetic marker for both RA and systemic lupus erythematosus susceptibility. Kurreeman et al. [2] applied the candidate gene approach to the *TRAF1-C5* region and found a polymorphism that increased the susceptibility and severity of RA. Plenge

et al. [3] studied 14 candidate genes and found significant associations between RA and *PTPN22*, *CTLA4*, and *PADI4*. Although many genes have shown suggestive connections with RA, only *HLADRB1* and *PTPN22* have been confirmed to increase the genetic risk of developing RA [4]. An explanation for the large number of identified genes might lie in the existence of gene-gene interactions, which, while helpful in identifying and compiling genes, also made the analysis much more complicated.

The traditional approaches used in association studies analyze markers marginally one at a time. As a result, valuable information on the interactions of genes was lost. Zheng et al. [5] proposed an association measure, the genotype-trait distortion (GTD), for evaluating association information on unphased multilocus genotypes from case-control data. GTD was shown to be able to capture interactions between markers that were associated with the disease [5].

Many current association studies are based on dense single-nucleotide polymorphism (SNP) data, with multiple SNPs corresponding to one gene. SNP-based methods are used to identify and replicate the most significant SNP. Without considering the dependence and functional relevance among SNPs within the same gene, most SNP-based association analysis may lead to false-negative results. As marker density increases, one could consider a gene-based analysis that offers a number of advantages, for instance, taking into account possible multiple disease-associated functional variants within a gene and overcoming the dependence among SNPs due to close proximity. In this study, we used the GTD score and applied a gene-based analysis on two sets of RA candidate genes from the North American Rheumatoid Arthritis Consortium (NARAC) data as part of Problem 1 of the Genetic Analysis Workshop 16 (GAW16).

Methods

Gene Set I

The Illumina data set of GAW16 Problem 1 consists of 545,080 SNPs genotyped on 868 RA cases and 1194 unaffected controls from NARAC. In our study, 531 SNPs from 27 candidate gene regions were considered (Table 1). The SNPs numbers and locations were identified by using the SNP mapping information from the National Cancer Institute's Cancer Genetic Markers of Susceptibility (CGEMS) initiative [6]. We included all related SNPs within each gene in the analysis. These 27 candidate genes were selected based on our search of the RA literatures. Among these 27 candidate genes, *HLADRB1* and *PTPN22* have been widely studied and confirmed to be associated with RA risk. Some of the

candidate genes (*PADI4*, *FCRL3*, *FCGR3*, *TNFRSF1B*, *STAT4*, *CTLA4*, *IL4*, *HAVCR1*, *TNF*, *MICA*, *NFKBIL1*, *OLIG3-TNFAIP3*, *TRAF1-C5*, *MHC2TA*, and *MIF*) have been replicated in different populations. A few candidate genes (*IL10*, *BTLA*, *IL1B*, *ITGAV*, *SLC22A4*, *IL3*, *VEGF*, and *RUNX1*) showed positive association in individual studies but have not been replicated in other independent data sets. In addition, we also included *DLG5* and *CARD15* because they were found to be associated with several autoimmune diseases. SNPs with missing data were imputed by fastPhase [7].

Gene Set II

After the gene \times gene interaction group discussion during the GAW16 conference, 24 candidate genes were selected for further analysis based on the contributors' findings (Table 1), 17 of which were considered in our original analysis (Gene Set I). The seven added genes are *IL13*, *HLA-A*, *HLA-B*, *HLA-C*, *LTA*, *IL6*, and *MS4A1*, which were identified in other contributors' studies. In other words, we applied our method to re-analyze the same RA data with different candidate genes from Gene Set I.

Methods

Given k SNP makers, there are 3^k possible unphased genotypes. We can use the following GTD statistic defined on the sum of squared difference between genotypes' relative frequency among the cases and controls to measure the joint effects of these k SNPs on the disease status, i.e.,

$$\nu = \sum_{s=1}^{3^k} \left(\frac{n_{D,s}}{n_D} - \frac{n_{U,s}}{n_U} \right)^2. \quad (1)$$

The statistic ν and its variations have been applied successfully in a number of studies [5,8-10]. Specifically, GTD was applied to a candidate gene study of RA during GAW15 [10] and identified significant higher-order interactions that were missed by other methods such as the multifactor dimensionality reduction (MDR) [10-12].

To identify significant interactions, we applied 1000 permutations of the case-control outcomes as in Lo et al. [13]. Based on ν , we applied the following gene-based analysis procedures developed by Lo et al. [13] to analyze our data sets:

1. Suppose that there are l genes with m_i SNPs in gene i and the total number of SNPs is m ($\sum m_i = m$). For example, $l = 27$ and $m = 531$ in Gene Set I. We calculated $\nu_{i,d}$ for SNP d of gene i ($k = 1$) and took an average over the m_i SNPs for each gene i , which resulted in l averages of the marginal effect of each gene.

Table 1: RA candidate genes

Gene	Gene Set I	Gene Set II	Locus	SNPs
PTPN22	Yes	Yes	1p13	12
PADI4	Yes	Yes	1p36.13	18
FCRL3	Yes	No	1q21.2-q22	8
FCGR3	Yes	Yes	1q23	4
IL10	Yes	No	1q31-q32	16
TNFRSF1B	Yes	Yes	1p36.3-p36.2	21
IL1B	Yes	Yes	2q14	7
ITGAV	Yes	Yes	2q31	16
STAT4	Yes	Yes	2q32.2-q32.3	30
CTLA4	Yes	Yes	2q33	5
BTLA	Yes	Yes	3q13.2	6
SLC22A4	Yes	Yes	5q31	19
IL13	No	Yes	5q31	6
IL3	Yes	Yes	5q31.1	3
IL4	Yes	No	5q31.1	7
HAVCR1	Yes	No	5q33.2	15
VEGF	Yes	Yes	6p12	12
HLADRB1	Yes	Yes	6p21.3	5
MICA	Yes	No	6p21.3	32
HLA-A	No	Yes	6p21.3	6
HLA-B	No	Yes	6p21.3	24
HLA-C	No	Yes	6p21.3	29
LTA	No	Yes	6p21.3	11
NFKBIL1	Yes	Yes	6p21.3	19
TNF	Yes	Yes	6p21.3	10
OLIG3 - TNFAIP3	Yes	No	6q23	76
IL6	No	Yes	7q21	14
TRAF1-CS	Yes	Yes	9q33-q34	31
DLG5	Yes	No	10q23	17
MS4A1	No	Yes	11q31	13
MHC2TA	Yes	No	16p13	12
CARD15	Yes	No	16q12	11
RUNX1	Yes	No	21q22.3	104
MIF	Yes	Yes	22q11.2	15

2. We randomly permuted the labels of case ($Y = 1$) and control ($Y = 0$) and repeated Step 1 on the permuted data while the original dependence among SNPs in each gene were retained.

3. To find the pair-wise interaction among the l genes, we examined $l \times (l-1)/2$ gene pairs. We first calculated the interaction genotype statistics $v_{i_d j_e}$ for $m \times (m-1)/2$ SNP pairs ($k = 2$) and defined the SNP-wise interaction as the ratio of incremental interaction versus the maximum of the two marginal effects as in Eq. (2) where “v” stands for maximum of the two values.

$$r(i_d, j_e) = \frac{v_{i_d j_e} - v_{i_d} \vee v_{j_e}}{v_{i_d} \vee v_{j_e}} \quad (2)$$

Second, we defined the interaction between genes i and j as the average of all SNP-wise ratios in Eq. (3). The ratio is termed as the “mean interaction ratio,” *Mean-ratio*, or R statistic. In addition, we also defined the gene-level “average maximum marginal,” or M , as in Eq. (4).

$$R_{ij} = \frac{\sum_{d=1}^{m_i} \sum_{e=1}^{m_j} r(i_d, j_e)}{m_i m_j} \quad (3)$$

$$M_{ij} = \frac{\sum_{d=1}^{m_i} \sum_{e=1}^{m_j} (v_{i_d} \vee v_{j_e})}{m_i m_j} \quad (4)$$

4. Applying the calculation outlined in Step 3 on the permuted data sets, we obtained a set of $l \times (l-1)/2$ values $\{(M_{ij}^{(p)}, R_{ij}^{(p)}); 1 \leq i < j \leq l\}$ for each permutation p . The *Mean-ratio curve method* of the following was applied to identify significant gene-pairs. All $1000 \times l \times (l-1)/2$ points were put on the (M, R) plane and separated into 100 bins according to the M values. Each bin had $10 \times l \times (l-1)/2$ points. For each bin, we identified the 99 percentile of the R statistics (R^*) that fell within this bin. By fitting a smoothing spline between the mid-values of each bin (M^*) and R^* , we constructed the 99% R threshold curve conditioning on M . We identified gene-pairs with observed R statistics above the threshold curve as significant.

5. In addition to the mean ratio R , we used another measure of interaction, the *Quantile-ratio* statistic. The Q statistic is calculated as the 90th or 95th-quantile of the SNP-wise ratios formed by the $m_i m_j$ SNP pairs. Significant Q_{ij} values were identified by the *curve* method.

6. An alternative way to evaluate the statistical significance is the *Rank* method. Similar to Step 4, we have $10 \times l \times (l-1)/2$ points in each bin. The values of R in each bin are ranked from 1 to $10 \times l \times (l-1)/2$. For each gene pair, the observed R value received such a rank value T , and the R value from permutation p received a rank value $T^{(p)}$. The p -value of the gene-pair is then the proportion of $T^{(p)} \geq T$. In this study a significance level of 0.01 is used. The same procedure can also be applied to the Q statistics calculated in Step 5.

Results

From the average maximum marginal statistics, we observed that all *HLADRB1*-related gene pairs have the strongest M values. We applied both *Mean-ratio* and *Quantile-ratio* methods to capture the interactions. Thirteen interactions are significant at ($p < 0.01$) by the *Rank* method. Seven interactions were identified by the quantile method at 90th and 95th level. One interaction (*ITGAV* and *VEGF*) was identified by the 90th-*Quantile Rank* method. The *Curve* method identified 10 interactions, all of which were overlapping with that of the *Rank* method. Table 2 shows the detailed selection results. In

Figure 1, we reported the 14 significant gene-gene interactions from Gene Set I (3.51 significant interactions expected by chance) using red lines.

For Gene Set II (2.76 significant interactions expected by chance), in addition to the interactions identified for Gene Set I (Table 2), another seven interactions were found to be significant by the *Mean-ratio Rank* method and two additional interactions were found significant by the *Curve* method. Figure 1 displays the extended networks with these interactions. As seen in Figure 1, *MIF* seems to be a "hub" in the association network with nine significant interactions. In addition, *IL3*, *VEGF*, and *HLA-B* also have at least five significant interactions.

Morand et al. [14] suggested that *MIF* is a pivotal mediator of RA. In addition, it has been implicated in many roles such as leukocyte recruitment, activation, and the production of pro-inflammatory cytokines. All of the roles contributed to the pathology of RA and showed the importance of *MIF*. Many interactions identified in our study have been previously discussed in the literature. It has been demonstrated that serum and synovial fluid levels of *MIF* were well correlated with the *VEGF* levels in patients with RA [15]. Nakahara et al. [16] indicated that *IL-6* blockade directly suppressed *VEGF* production in synovial fibroblasts and may consequently reduce serum *VEGF* levels in patients with RA. Kiriakidis et al. [17] also showed that *VEGF* production in human macrophages

Table 2: Selected interactions by different proposed procedures (p -value < 0.01)

Curve method			Rank method		
Mean Ratio	90% Quantile	95% Quantile	Mean Ratio	90% Quantile	95% Quantile
<i>IL3</i> <i>BTLA</i>	<i>IL3</i> <i>BTLA</i>	<i>IL3</i> <i>BTLA</i>	<i>IL3</i> <i>BTLA</i>	<i>IL3</i> <i>MIF</i> ^a	<i>IL3</i> <i>BTLA</i>
<i>IL3</i> <i>MIF</i>	<i>IL3</i> <i>MIF</i>	<i>IL3</i> <i>MIF</i>	<i>IL3</i> <i>MIF</i>	<i>IL3</i> <i>PADI4</i>	<i>IL3</i> <i>MIF</i>
<i>IL3</i> <i>PADI4</i>	<i>IL3</i> <i>PADI4</i>	<i>IL3</i> <i>PADI4</i>	<i>IL3</i> <i>PADI4</i>	<i>IL3</i> <i>TRAF1-C5</i> ^a	<i>IL3</i> <i>PADI4</i>
<i>IL3</i> <i>SLC22A4</i>	<i>IL3</i> <i>TRAF1-C5</i>	<i>IL3</i> <i>TRAF1-C5</i>	<i>IL3</i> <i>SLC22A4</i>	<i>ITGAV</i> <i>VEGF</i>	<i>MIF</i> <i>BTLA</i>
<i>IL3</i> <i>TNFRSF1B</i>	<i>MIF</i> <i>BTLA</i>	<i>MIF</i> <i>BTLA</i>	<i>IL3</i> <i>TNFRSF1B</i>	<i>MIF</i> <i>BTLA</i> ^a	<i>MIF</i> <i>FCGR3A</i>
<i>IL3</i> <i>TRAF1-C5</i>	<i>MIF</i> <i>FCGR3A</i>		<i>IL3</i> <i>TRAF1-C5</i>	<i>MIF</i> <i>FCGR3A</i> ^a	<i>MIF</i> <i>TRAF1-C5</i>
<i>MIF</i> <i>BTLA</i>	<i>MIF</i> <i>TRAF1-C5</i>		<i>MIF</i> <i>BTLA</i>	<i>MIF</i> <i>TRAF1-C5</i> ^a	
<i>MIF</i> <i>FCGR3A</i>	<i>FCGR3A</i>		<i>MIF</i> <i>FCGR3A</i>		
<i>MIF</i> <i>ITGAV</i>	<i>TRAF1-C5</i> ^a		<i>MIF</i> <i>HLA-B</i> ^a		
<i>MIF</i> <i>TRAF1-C5</i>			<i>MIF</i> <i>ITGAV</i>		
<i>MIF</i> <i>CTLA4</i> ^a			<i>MIF</i> <i>TNFRSF1B</i> ^a		
			<i>MIF</i> <i>TRAF1-C5</i>		
			<i>MIF</i> <i>VEGF</i>		
			<i>NFKBIL1</i> <i>HLA-B</i> ^a		
			<i>NFKBIL1</i> <i>VEGF</i>		
			<i>NFKBIL1</i> <i>TNF</i>		
			<i>VEGF</i> <i>IL6</i> ^a		
			<i>VEGF</i> <i>HLA-B</i> ^a		
			<i>HLA-A</i> <i>HLA-B</i> ^a		
			<i>HLA-B</i> <i>HLA-C</i> ^a		

^a Significant interactions only identified in Gene Set II.




Figure 1

Association network with significant interactions identified. All significant interactions identified for Gene Set II are plotted. Interactions in red were also identified in Gene Set I. Different line widths indicate interactions identified by different numbers of proposed procedures.

was NF- κ B-dependent, which agreed with our finding of interaction between *VEGF* and *NFKBIL1*. *VEGF* may be directly involved in the activation of RA monocytes and synoviocytes, producing *TNF* and *IL-6* via a receptor-coupling event [18]. As noted in Yoo et al. [18], this may imply a direct interaction between *VEGF* and *IL-6* or an indirect interaction between *VEGF* and *TNF* via *NFKBIL1*, also found in our results. Onodera et al. [19] demonstrated that *MIF* enhanced NFKB binding activities of the nuclear extracts from RA synovial fibroblasts. The *NFKBIL1*, a divergent member of I- κ -B proteins that is an inhibitor for NFKB complex, may have potential interaction between *MIF* and *NFKBIL1*. In Figure 1, we showed that the indirect connection between *MIF* and *NFKBIL1* via *VEGF*. Furthermore, the relation between *TNF* and NFKB-dependent signaling pathway of RA patients was discussed by Youn et al. [20].

Conclusion

In this paper, many relevant candidate regions reported in the literature were chosen for a more detailed analysis. We applied a recently developed method by Lo et al. [13] to identify potential gene-gene interactions that are associated with the susceptibility of RA. First, we found a strong marginal signal between *HLADRB1* and RA. In addition, the *Rank* and the *Curve* methods based on 1000 permutations identified a number of gene-pairs that are significantly associated with RA, many of which

were previously reported in the literature. The association network constructed in our paper may offer additional evidence and insight on gene-gene interactions in the development of RA. Additional experiments and independent data are required to confirm our findings.

List of abbreviations used

CGEMS: Cancer Genetic Markers of Susceptibility; GAW16: Genetic Analysis Workshop 16; GTD: Genotype-trait distortion; NARAC: North American Rheumatoid Arthritis Consortium; RA: Rheumatoid arthritis; SNP: Single-nucleotide polymorphism.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SL and TZ conceived and designed the research. C-HH, BQ, and LC carried out the data analysis and computation. C-HH, JX, S-HL, and TZ analyzed the results and prepared the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The Genetic Analysis Workshops are supported by NIH grant R01 GM031575 from the National Institute of General Medical Sciences. The CGEMS SNPs mapping information were requested and accessed with Data Access Committee of the National Cancer Institute permission and

accessed via the protected portal at <http://cgems.cancer.gov/data/>. This research was supported by NIH grant R01 GM070789 and NSF grant DMS 0714669.

This article has been published as part of *BMC Proceedings* Volume 3 Supplement 7, 2009: Genetic Analysis Workshop 16. The full contents of the supplement are available online at <http://www.biomedcentral.com/1753-6561/3?issue=S7>.

References

- Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, de Bakker PI, Le JM, Lee HS, Batliwalla F, Li W, Masters SL, Booty MG, Carulli JP, Padyukov L, Alfredsson L, Klareskog L, Chen WV, Amos CI, Criswell LA, Seldin MF, Kastner DL and Gregersen PK: **STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus.** *N Engl J Med* 2007, **357**:977–986.
- Kurreeman FA, Padyukov L, Marques RB, Schrodin SJ, Seddighzadeh M, Stoeken-Rijsbergen G, Helm-van Mil van der AH, Allaart CF, Verduyn W, Houwing-Duistermaat J, Alfredsson L, Begovich AB, Klareskog L, Huizinga TW and Toes RE: **A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis.** *PLoS Med* 2007, **4**:e278.
- Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW, Wolfe F, Kastner DL, Alfredsson L, Altshuler D, Gregersen PK, Klareskog L and Rioux JD: **Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4.** *Am J Hum Genet* 2005, **77**:1044–1060.
- Bowes J and Barton A: **Recent advances in the genetics of RA susceptibility.** *Rheumatology* 2008, **47**:399–402.
- Zheng T, Wang H and Lo SH: **Backward genotype-trait association (BGTA)-based dissection of complex traits in case-control designs.** *Hum Hered* 2006, **62**:196–212.
- Meza JE, Brzovic PS, King MC and Kleit RE: **Mapping the functional domains of BRCA1 interaction of the ring finger domains of BRCA1 and BARD1.** *J Biol Chem* 1999, **274**:5659–5665.
- Scheet P and Stephens M: **A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase.** *Am J Hum Genet* 2006, **78**:629–644.
- Lo SH and Zheng T: **Backward haplotype transmission association (BHTA) algorithm - a fast multiple-marker screening method.** *Hum Hered* 2002, **53**:197–215.
- Lo SH and Zheng T: **A demonstration and findings of a statistical approach through reanalysis of inflammatory bowel disease data.** *Proc Natl Acad Sci USA* 2004, **101**:10386–10391.
- Ding Y, Cong L, Ionita-Laza I, Lo SH and Zheng T: **Constructing gene association networks for rheumatoid arthritis using the backward genotype-trait association (BGTA) algorithm.** *BMC Proc* 2007, **1**(suppl 1):S13.
- Ling M, Li X, Yang K, Cui J, Fang B, Guo X and Rotter JI: **Evaluating gene × gene and gene × smoking interaction in rheumatoid arthritis using candidate genes in GAW15.** *BMC Proc* 2007, **1**(suppl 1):S17.
- Ritchie MD, Bartlett J, Bush WS, Edwards TL, Motsinger AA and Torstenson ES: **Exploring epistasis in candidate genes for rheumatoid arthritis.** *BMC Proc* 2007, **1**(suppl 1):S70.
- Lo SH, Chernoff H, Cong L, Ding Y and Zheng T: **Discovering interaction among BRCA1 and other candidate genes associated with sporadic breast cancer.** *Proc Natl Acad Sci USA* 2008, **105**:12387–12392.
- Morand EF, Leech M and Bernhagen J: **MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis.** *Nat Rev Drug Discov* 2006, **5**:399–410.
- Kim HR, Park MK, Cho ML, Yoon CH, Lee SH, Park SH, Leng L, Bucala R, Kang I, Choe J and Kim HY: **Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis.** *J Rheumatol* 2007, **34**:927–936.
- Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K and Nishimoto N: **Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.** *Arthritis Rheum* 2003, **48**:1521–1529.
- Kiriakidis S, Andreacos E, Monaco C, Foxwell B, Feldmann M and Paleolog E: **VEGF expression in human macrophages is NF-κB-dependent: studies using adenoviruses expressing the endogenous NF-κB inhibitor IκBα and a kinase defective form of the IκB kinase 2.** *J Cell Sci* 2003, **116**:665–674.
- Yoo SA, Bae DG, Ryoo JW, Kim HR, Park GS, Cho CS, Chae CB and Kim WU: **Arginine-rich anti-vascular endothelial growth factor (Anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-α and IL-6 by human monocytes.** *J Immunol* 2005, **174**:5846–5855.
- Onodera S, Nishihira J, Koyama Y, Majima T, Aoki Y, Ichiyama H, Ishibashi T and Minami A: **Macrophage migration inhibitory factor up-regulates the expression of interleukin-8 messenger RNA in synovial fibroblasts of rheumatoid arthritis patients: common transcriptional regulatory mechanism between interleukin-8 and interleukin-1β.** *Arthritis Rheum* 2004, **50**:1437–1447.
- Youn J, Kim HY, Park JH, Hwang SH, Lee SY, Cho CS and Lee SK: **Regulation of TNF-α-mediated hyperplasia through TNF receptors, TRAFs, and NF-κB in synoviocytes obtained from patients with rheumatoid arthritis.** *Immunol Lett* 2002, **83**:85–93.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

